Synthesis and Evaluation of N-[1-(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the Treatment of Diseases Belonging to MAOs

<div>IC50 (μM) of the selected compounds (4a, 4b, and 4c) and control drugs against MAO-B enzyme. (a) Selegiline (0.038 μM); (b) 4a (0.42 μM); (c) 4b (0.36 μM); (d) 4c (0.69 μM).</div>

Journal of Chemistry

fig2

Figure 2

Figure 2: Synthesis and Evaluation of N-[1-(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the Treatment of Diseases Belonging to MAOs

Figure 2 | Synthesis and Evaluation of N-[1-(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the Treatment of Diseases Belonging to MAOs 